Dick de Zeeuw
The University of Sydney
3 papers in the Anchorcite directory, published between 2001 and 2019, cited 21,977 times in total.
ORCID profileResearch topics
- Chronic Kidney Disease and Diabetes · 3 papers
- Diabetes Treatment and Management · 2 papers
- Heart Failure Treatment and Management · 1 paper
- Renin-Angiotensin System Studies · 1 paper
- Renal Diseases and Glomerulopathies · 1 paper
- Acute Kidney Injury Research · 1 paper
Frequent co-authors
- Bruce Charles Neal · 2 papers
- Vlado Perkovic · 2 papers
- Kenneth W. Mahaffey · 2 papers
- Barry Morton Brenner · 2 papers
- Greg Fulcher · 1 paper
- Ngozi Erondu · 1 paper
- Wayne C. Shaw · 1 paper
- Gordon Law · 1 paper
Papers
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine · 2017 · 8,032 citations
Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The…
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2001 · 7,523 citations
BACKGROUND: Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin-angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the…
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations
BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…
Metadata from OpenAlex (CC0).